Form 4: Alnylam Executive's Stock Transactions

Alnylam Pharmaceuticals' CSO and EVP, Kevin Fitzgerald, reported the vesting of performance-based stock units and subsequent sell-to-cover transactions for tax obligations.

Summary

• Kevin Joseph Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, Inc. (ALNY), reported recent stock transactions.
• On January 11, 2026, 3,800 shares of common stock were acquired due to the vesting of performance-based stock units (PSUs).
• This PSU vesting was triggered by Alnylam publicly reporting $2.5 billion in annual net product revenue, a milestone determined by the People, Culture and Compensation Committee on January 11, 2026.
• A total of 4,010 shares of common stock were disposed of on January 12 and 13, 2026.
• These dispositions were automatic "sell-to-cover" transactions to satisfy minimum statutory tax withholding obligations.
• The sales were executed under a Rule 10b5-1(c) trading plan, which was adopted on August 14, 2025.
• Weighted average sales prices for the disposed shares ranged from $353.95 to $377.82 on January 12, 2026, and from $367.52 to $374.33 on January 13, 2026.
• Following these transactions, direct beneficial ownership stands at 21,264 shares, with an additional 537 shares held indirectly through a managed 401(k) account.

Sentiment

Score: 7

Explanation: The achievement of a significant revenue milestone is positive, even if the executive sold shares for tax purposes, as these sales were pre-planned.

Positives

• Alnylam Pharmaceuticals achieved a significant performance milestone by publicly reporting $2.5 billion in annual net product revenue, leading to the vesting of performance-based stock units.
• The executive's stock sales were pre-planned under a Rule 10b5-1(c) trading plan, indicating a structured approach to managing equity compensation and tax obligations rather than discretionary selling.

Negatives

• An executive disposed of a substantial number of shares (4,010 shares), which, despite being for tax purposes, reduces insider ownership.

Future Outlook

The company has successfully met a key performance metric of $2.5 billion in annual net product revenue, which could imply continued strong performance, though no explicit forward guidance is provided.

Management Comments

• The People, Culture and Compensation Committee of the Issuer Board of Directors determined on January 11, 2026, that the issuer publicly reported $2.5 billion in annual net product revenue in accordance with GAAP, triggering PSU vesting.

Industry Context

The achievement of a $2.5 billion annual net product revenue milestone is a strong indicator of commercial success for a biotechnology company like Alnylam Pharmaceuticals, suggesting effective product development and market penetration within the pharmaceutical industry.

Related Party Transactions

• The acquisition of shares through PSU vesting and subsequent sell-to-cover transactions are standard compensation and tax management practices for executives.
• Indirect ownership through the issuer's 401(k) plan, including matching contributions, is a common employee benefit.

Stakeholder Impact

• Shareholders: The achievement of the $2.5 billion revenue target is a positive indicator of company performance and execution against strategic goals. The executive's share sales, while for tax purposes, represent a reduction in direct insider holdings.
• Employees: The successful vesting of performance-based units for an executive demonstrates that company-wide performance targets are being met, which can positively influence morale and the effectiveness of incentive programs.

Key Dates

Recommendation

The company's achievement of a significant $2.5 billion annual net product revenue milestone is a strong positive signal for its operational performance and market position. However, the executive's subsequent sale of a notable number of shares, even if pre-planned for tax obligations, could be perceived as a slight negative by some investors. Given the strong operational performance balanced with insider selling, a "hold" recommendation is appropriate, suggesting investors maintain their current position while monitoring future developments.

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, insider trading, stock transactions, performance stock units, PSU, sell-to-cover, Rule 10b5-1, executive compensation, Kevin Fitzgerald